We are live on
!
Find out more
SCM
Silverarc Capital Management Portfolio holdings
AUM
$849M
1-Year Est. Return
470.8%
This Fund
S&P 500
This Quarter
Est. Return
+2.41%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$223M
AUM Growth
-$67.9M
(-23%)
Cap. Flow
-$50.4M
Cap. Flow
% of AUM
-22.66%
Top 10 Holdings %
Top 10 Hldgs %
38.27%
Holding
101
New
18
Increased
23
Reduced
24
Closed
32
Top Buys
| 1 |
MRUS
Merus
MRUS
|
+$6.87M |
| 2 |
ETNB
89bio
ETNB
|
+$5.71M |
| 3 |
KALV
KalVista Pharmaceuticals
KALV
|
+$5.4M |
| 4 |
Cogent Biosciences
COGT
|
+$5.12M |
| 5 |
Karyopharm Therapeutics
KPTI
|
+$5.07M |
Top Sells
| 1 |
Madrigal Pharmaceuticals
MDGL
|
+$10.9M |
| 2 |
MORF
Morphic Holding, Inc. Common Stock
MORF
|
+$10.4M |
| 3 |
Immunovant
IMVT
|
+$9.22M |
| 4 |
Xenon Pharmaceuticals
XENE
|
+$5.8M |
| 5 |
BLU
BELLUS Health Inc.
BLU
|
+$5.49M |
Sector Composition
| 1 | Healthcare | 95.65% |
| 2 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MRUS
1
DELISTED
Merus
MRUS
| $12.3M | 5.53% |
668,784
+394,080
| +143% | +$6.87M |
|
2
MacroGenics
MGNX
$270M
| $9.76M | 4.39% |
1,361,809
+749,334
| +122% | +$4.51M |
|
|
VRAY
3
DELISTED
ViewRay, Inc.
VRAY
| $9.67M | 4.34% |
2,793,748
+388,388
| +16% | +$1.64M |
|
|
PSTX
4
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
| $8.28M | 3.72% |
2,689,301
+459,301
| +21% | +$2.75M |
|
5
Oric Pharmaceuticals
ORIC
$1.11B
| $8.18M | 3.68% |
1,435,945
+199,649
| +16% | +$1.04M |
|
|
TERN
6
DELISTED
Terns Pharmaceuticals
TERN
| $7.91M | 3.55% |
667,922
-32,078
| -5% | -$307K |
|
|
AKRO
7
DELISTED
Akero Therapeutics
AKRO
| $7.75M | 3.48% |
202,561
+30,461
| +18% | +$1.36M |
|
8
Nuvalent
NUVL
$9.81B
| $7.35M | 3.3% |
281,533
-21,430
| -7% | -$634K |
|
|
BLU
9
DELISTED
BELLUS Health Inc.
BLU
| $7.2M | 3.24% |
1,000,000
-707,370
| -41% | -$5.49M |
|
|
ITCI
10
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $6.77M | 3.04% |
125,035
-15,331
| -11% | -$741K |
|
|
ETNB
11
DELISTED
89bio
ETNB
| $6.67M | 3% |
+438,215
| New | +$5.71M |
|
12
Viking Therapeutics
VKTX
$4.4B
| $6.33M | 2.84% |
+380,000
| New | +$3.93M |
|
|
13
Cogent Biosciences
COGT
$6.57B
| $6.25M | 2.81% |
579,264
+400,264
| +224% | +$5.12M |
|
|
14
Karyopharm Therapeutics
KPTI
$217M
| $6M | 2.69% |
+102,762
| New | +$5.07M |
|
|
KALV
15
DELISTED
KalVista Pharmaceuticals
KALV
| $5.69M | 2.56% |
+723,544
| New | +$5.4M |
|
16
Schrodinger
SDGR
$1.23B
| $5.6M | 2.52% |
212,825
+104,825
| +97% | +$2.49M |
|
17
Gilead Sciences
GILD
$162B
| $4.99M | 2.24% |
60,130
+8,168
| +16% | +$677K |
|
18
BioCryst Pharmaceuticals
BCRX
$2.41B
| $4.82M | 2.17% |
577,757
+305,584
| +112% | +$2.94M |
|
19
Veracyte
VCYT
$4.68B
| $4.68M | 2.1% |
209,653
+9,653
| +5% | +$233K |
|
20
Pharvaris
PHVS
$2.41B
| $4.51M | 2.02% |
559,387
+459,387
| +459% | +$4.04M |
|
21
United Therapeutics
UTHR
$22.3B
| $4.16M | 1.87% |
18,578
+2,530
| +16% | +$624K |
|
22
Vertex Pharmaceuticals
VRTX
$120B
| $4.15M | 1.87% |
13,181
+1,797
| +16% | +$539K |
|
23
Regeneron Pharmaceuticals
REGN
$69.1B
| $4.11M | 1.85% |
+5,000
| New | +$3.77M |
|
|
24
Xenon Pharmaceuticals
XENE
$6.48B
| $3.46M | 1.55% |
96,643
-157,012
| -62% | -$5.8M |
|
25
Cerus
CERS
$631M
| $3.42M | 1.54% |
1,152,902
-481,112
| -29% | -$1.45M |
|
Similar funds
BOTOTLSJU
EFG
LA
EPIMS
CFP
USAA
OMC
AIA